Edition:
United Kingdom

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

3.79USD
20 Aug 2018
Change (% chg)

$0.12 (+3.27%)
Prev Close
$3.67
Open
$3.68
Day's High
$3.84
Day's Low
$3.68
Volume
18,424
Avg. Vol
94,548
52-wk High
$5.13
52-wk Low
$1.79

Latest Key Developments (Source: Significant Developments)

MEI Pharma Says Selling Stockholders May Offer And Sell Up To 49.5 Mln Shares Of Co's Common Stock
Wednesday, 6 Jun 2018 

June 6 (Reuters) - MEI Pharma Inc ::MEI PHARMA INC SAYS SELLING STOCKHOLDERS MAY OFFER AND SELL UP TO 49.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Helsinn Group and MEI Pharma's Pracinostat receives orphan drug designation from European Medicines Agency
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Mei Pharma Inc ::HELSINN GROUP AND MEI PHARMA ANNOUNCE THAT PRACINOSTAT HAS RECEIVED ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML).  Full Article

MEI Pharma Announces FDA Clearance Of Investigational New Drug Application For CDK Inhibitor Voruciclib
Monday, 8 Jan 2018 

Jan 8 (Reuters) - MEI Pharma Inc ::MEI PHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CDK INHIBITOR VORUCICLIB.MEI PHARMA INC - LOOK FORWARD TO ADVANCING VORUCICLIB THROUGH CLINIC IN Q2 OF 2018.  Full Article

Mei Pharma enters into at-market equity offering sales agreement
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Mei Pharma Inc :On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​.Pursuant to sales agreement co may sell, from time to time, an aggregate of up to $30 million of common stock - SEC filing.  Full Article

MEI pharma reports fiscal year 2016 results
Tuesday, 6 Sep 2016 

MEI Pharma Inc :MEI Pharma reports fiscal year 2016 results.  Full Article

BRIEF-MEI Pharma And Helsinn Announce Positive Results In Myelodysplastic Syndrome Trial

* MEI PHARMA AND HELSINN GROUP ANNOUNCE SUCCESSFUL INTERIM ANALYSIS OF PRACINOSTAT/AZACITIDINE PHASE 2 COMBINATION STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (MDS) PATIENTS